Clinical trial
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
NCT00313183 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00313183 |
|---|---|
| Title | A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus |
| Official title | A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SYMLIN in Adolescent Subjects With Type 1 Diabetes Mellitus |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | pramlintide acetate |
| Enrollment | 12 |
| Start date | Apr 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Apr 12, 2006 |
| Last update posted | Mar 6, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: